ArticleWorld journal of surgical oncology2026
Multi-omics exploration of hypoxia in gastric cancer.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spatial immune niches in gastric cancer immunotherapy resistance: mechanisms and translational implications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypoxia created an intratumoral oxygen gradient, promoting a more aggressive tumoral phenotype. Nevertheless, there was a lack of hypoxic panorama in gastric cancer (GC).
methodsA total of 715 GC samples covering two independent cohorts were used for non-negative matrix factorization clustering and subtype exploration based on a tailored hypoxic signature. The prognosis, molecular markers, pathways, infiltrating of lymphocytes and stromal cells, and response of PD-1 therapy were compared between the subtypes.
resultsGC patients were divided into two groups, one indicted as normoxia, while the other defined as hypoxia. Hallmarks of aggressive tumor features such as EMT, angiogenesis, and KRAS signaling up were significantly enriched under hypoxic conditions and undoubtedly, worse outcome. Additionally, hypoxia confers GC with higher immune score, CAF infiltration, and resistant to pembrolizumab therapy in patients with metastatic GC (mGC).
conclusionsHypoxia-targeted or CAF-oriented therapy may overcome current chemoradiotherapy-resistant advanced GC but warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.